Core Laboratories N.V. (NYSE:CLB) has received a consensus recommendation of “Hold” from the sixteen research firms that are covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $123.00.

Several research firms have issued reports on CLB. Zacks Investment Research lowered shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Tuesday, April 11th. Loop Capital upgraded shares of Core Laboratories N.V. from a “hold” rating to a “buy” rating and lifted their price target for the stock from $125.00 to $130.00 in a research report on Friday, April 21st. ABN Amro upgraded shares of Core Laboratories N.V. to a “hold” rating in a research report on Friday, April 21st. Scotiabank set a $136.00 price target on shares of Core Laboratories N.V. and gave the stock a “hold” rating in a research report on Saturday, April 22nd. Finally, Tudor Pickering began coverage on shares of Core Laboratories N.V. in a research report on Thursday, March 23rd. They issued a “hold” rating on the stock.

ILLEGAL ACTIVITY NOTICE: “Core Laboratories N.V. (CLB) Given Average Rating of “Hold” by Analysts” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/07/21/core-laboratories-n-v-clb-given-average-rating-of-hold-by-analysts.html.

Core Laboratories N.V. (CLB) traded down 2.02% during midday trading on Friday, reaching $105.69. The company had a trading volume of 780,049 shares. The company has a market capitalization of $4.67 billion, a P/E ratio of 69.99 and a beta of 1.60. The company’s 50 day moving average is $103.54 and its 200-day moving average is $111.27. Core Laboratories N.V. has a 52-week low of $96.30 and a 52-week high of $125.83.

Core Laboratories N.V. (NYSE:CLB) last posted its quarterly earnings results on Wednesday, April 19th. The oil and gas company reported $0.42 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.39 by $0.03. The firm had revenue of $157.81 million for the quarter, compared to analyst estimates of $150.44 million. Core Laboratories N.V. had a net margin of 11.10% and a return on equity of 43.28%. The firm’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.37 earnings per share. Equities analysts expect that Core Laboratories N.V. will post $2.18 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 14th. Investors of record on Monday, July 17th will be paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 2.08%. The ex-dividend date is Thursday, July 13th. Core Laboratories N.V.’s dividend payout ratio is 145.70%.

Several large investors have recently modified their holdings of the stock. Banced Corp raised its stake in shares of Core Laboratories N.V. by 3.0% in the first quarter. Banced Corp now owns 2,894 shares of the oil and gas company’s stock worth $334,000 after buying an additional 84 shares during the period. Bank of Montreal Can raised its stake in shares of Core Laboratories N.V. by 462.4% in the first quarter. Bank of Montreal Can now owns 163,920 shares of the oil and gas company’s stock worth $18,937,000 after buying an additional 134,773 shares during the period. WCM Investment Management CA raised its stake in shares of Core Laboratories N.V. by 4.6% in the first quarter. WCM Investment Management CA now owns 4,130,102 shares of the oil and gas company’s stock worth $477,109,000 after buying an additional 181,025 shares during the period. Gulf International Bank UK Ltd raised its stake in shares of Core Laboratories N.V. by 3.1% in the first quarter. Gulf International Bank UK Ltd now owns 13,449 shares of the oil and gas company’s stock worth $1,553,000 after buying an additional 400 shares during the period. Finally, Sheets Smith Wealth Management raised its stake in shares of Core Laboratories N.V. by 142.7% in the first quarter. Sheets Smith Wealth Management now owns 12,245 shares of the oil and gas company’s stock worth $1,415,000 after buying an additional 7,200 shares during the period.

Core Laboratories N.V. Company Profile

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Analyst Recommendations for Core Laboratories N.V. (NYSE:CLB)

Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.